Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)

Tommaso    B.    Jannini; Giorgio   D.   Lorenzo; Emanuela       Bianciardi; Cinzia       Niolu; Massimiliano       Toscano; Giacomo       Ciocca; Emmanuele    A.    Jannini; Alberto      Siracusano
Abstract

Psychiatric drugs have primacy for off-label prescribing. Among those, selective serotonin reuptake inhibitors (SSRIs) are highly versatile and, therefore, widely prescribed. Moreover, they are commonly considered as having a better safety profile compared to other antidepressants. Thus, when it comes to off-label prescribing, SSRIs rank among the top positions. In this review, we present the state of the art of off-label applications of selective serotonin reuptake inhibitors, ranging from migraine prophylaxis to SARS-CoV-2 antiviral properties. Research on SSRIs provided significant evidence in the treatment of premature ejaculation, both with the on-label dapoxetine 30 mg and the off-label paroxetine 20 mg. However, other than a serotoninergic syndrome, serious conditions like increased bleeding rates, hyponatremia, hepatoxicity, and post-SSRIs sexual dysfunctions, are consistently more prominent when using such compounds. These insidious side effects might be frequently underestimated during common clinical practice, especially by nonpsychiatrists. Thus, some points must be addressed when using SSRIs. Among these, a psychiatric evaluation before every administration that falls outside the regulatory agencies-approved guidelines has to be considered mandatory. For these reasons, we aim with the present article to identify the risks of inappropriate uses and to advocate the need to actively boost research encouraging future clinical trials on this topic.
Keywords: SSRI, premature ejaculation, off-label, antidepressants, PSSD, hypersexuality, paraphilic disorders.
Graphical Abstract

[1] 
Radley, D.C.; Finkelstein, S.N.; Stafford, R.S. Off-label prescribing among office-based physicians. Arch. Intern. Med.,  2006, 166(9), 1021-1026.
[http://dx.doi.org/10.1001/archinte.166.9.1021] [PMID:  16682577] 
[2] 
Alexander, G.C.; Gallagher, S.A.; Mascola, A.; Moloney, R.M.; Stafford, R.S. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol. Drug Saf.,  2011, 20(2), 177-184.
[http://dx.doi.org/10.1002/pds.2082] [PMID:  21254289] 
[3] 
Eguale, T.; Buckeridge, D.L.; Winslade, N.E.; Benedetti, A.; Hanley, J.A.; Tamblyn, R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch. Intern. Med.,  2012, 172(10), 781-788.
[http://dx.doi.org/10.1001/archinternmed.2012.340] [PMID:  22507695] 
[4] 
Stafford, R.S. Regulating off-label drug use--rethinking the role of the FDA. N. Engl. J. Med.,  2008, 358(14), 1427-1429.
[http://dx.doi.org/10.1056/NEJMp0802107] [PMID:  18385495] 
[5] 
Faquih, A.E.; Memon, R.I.; Hafeez, H.; Zeshan, M.; Naveed, S. A review of novel antidepressants: a guide for clinicians. Cureus,  2019, 11(3), e4185.
[http://dx.doi.org/10.7759/cureus.4185] [PMID:  31106085] 
[6] 
Lochmann, D.; Richardson, T. Selective serotonin reuptake inhibitors. Handb. Exp. Pharmacol.,  2019, 250, 135-144.
[http://dx.doi.org/10.1007/164_2018_172] [PMID:  30838457] 
[7] 
Appleton, S.M. Premenstrual Syndrome: Evidence-based evaluation and treatment. Clin. Obstet. Gynecol.,  2018, 61(1), 52-61.
[http://dx.doi.org/10.1097/GRF.0000000000000339] [PMID:  29298169] 
[8] 
Poluzzi, E.; Piccinni, C.; Sangiorgi, E.; Clo, M.; Tarricone, I.; Menchetti, M.; De Ponti, F. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. Eur. J. Clin. Pharmacol.,  2013, 69(12), 2095-2101.
[http://dx.doi.org/10.1007/s00228-013-1567-8] [PMID:  23904053] 
[9] 
Wong, J.; Motulsky, A.; Abrahamowicz, M.; Eguale, T.; Buckeridge, D.L.; Tamblyn, R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ,  2017, 356, j603.
[http://dx.doi.org/10.1136/bmj.j603] [PMID:  28228380] 
[10] 
Qin, B. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: A meta-analysis of efficacy and acceptability. Clin. Ther.,  2014, 36(7), 1087-1095.
[http://dx.doi.org/10.1016/j.clinthera.2014.06.001] 
[11] 
Coupland, C.; Hill, T.; Morriss, R.; Moore, M.; Arthur, A.; Hippisley-Cox, J. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. BMC Med.,  2018, 16(1), 36.
[http://dx.doi.org/10.1186/s12916-018-1022-x] [PMID:  29514662] 
[12] 
Murphy, T.K.; Segarra, A.; Storch, E.A.; Goodman, W.K. SSRI adverse events: how to monitor and manage. Int. Rev. Psychiatry,  2008, 20(2), 203-208.
[http://dx.doi.org/10.1080/09540260801889211] [PMID:  18386213] 
[13] 
Johnson, C.F.; Macdonald, H.J.; Atkinson, P.; Buchanan, A.I.; Downes, N.; Dougall, N. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br. J. Gen. Pract.,  2012, 62(604), e773-e779.
[http://dx.doi.org/10.3399/bjgp12X658304] [PMID:  23211181] 
[14] 
Petty, D.R.; House, A.; Knapp, P.; Raynor, T.; Zermansky, A. Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing,  2006, 35(5), 523-526.
[http://dx.doi.org/10.1093/ageing/afl023] [PMID:  16690637] 
[15] 
Moore, M.; Yuen, H.M.; Dunn, N.; Mullee, M.A.; Maskell, J.; Kendrick, T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ,  2009, 339, b3999.
[http://dx.doi.org/10.1136/bmj.b3999] [PMID:  19833707] 
[16] 
Johnson, C.F.; Williams, B.; MacGillivray, S.A.; Dougall, N.J.; Maxwell, M. ‘Doing the right thing’: factors influencing GP prescribing of antidepressants and prescribed doses. BMC Fam. Pract.,  2017, 18(1), 72.
[http://dx.doi.org/10.1186/s12875-017-0643-z] [PMID:  28623894] 
[17] 
Adly, C.; Straumanis, J.; Chesson, A. Fluoxetine prophylaxis of migraine. Headache,  1992, 32(2), 101-104.
[http://dx.doi.org/10.1111/j.1526-4610.1992.hed3202101.x] [PMID:  1551787] 
[18] 
Bánk, J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache,  1994, 34(8), 476-478.
[http://dx.doi.org/10.1111/j.1526-4610.1994.hed3408476.x] [PMID:  7960733] 
[19] 
d’Amato, C.C.; Pizza, V.; Marmolo, T.; Giordano, E.; Alfano, V.; Nasta, A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache,  1999, 39(10), 716-719.
[http://dx.doi.org/10.1046/j.1526-4610.1999.3910716.x] [PMID:  11279947] 
[20] 
Krymchantowski, A.V.; Silva, M.T.; Barbosa, J.S.; Alves, L.A. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache,  2002, 42(6), 510-514.
[http://dx.doi.org/10.1046/j.1526-4610.2002.02125.x] [PMID:  12167139] 
[21] 
Landy, S.; McGinnis, J.; Curlin, D.; Laizure, S.C. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache,  1999, 39(1), 28-32.
[http://dx.doi.org/10.1046/j.1526-4610.1999.3901028.x] [PMID:  15613191] 
[22] 
Steiner, T.J.; Ahmed, F.; Findley, L.J.; MacGregor, E.A.; Wilkinson, M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia,  1998, 18(5), 283-286.
[http://dx.doi.org/10.1046/j.1468-2982.1998.1805283.x] [PMID:  9673809] 
[23] 
Tarlaci, S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin. Neuropharmacol.,  2009, 32(5), 254-258.
[http://dx.doi.org/10.1097/WNF.0b013e3181a8c84f] [PMID:  19667978] 
[24] 
Hollander, E.; Allen, A.; Kwon, J.; Aronowitz, B.; Schmeidler, J.; Wong, C.; Simeon, D. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch. Gen. Psychiatry,  1999, 56(11), 1033-1039.
[http://dx.doi.org/10.1001/archpsyc.56.11.1033] [PMID:  10565503] 
[25] 
Perugi, G.; Giannotti, D.; Di Vaio, S.; Frare, F.; Saettoni, M.; Cassano, G.B. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int. Clin. Psychopharmacol.,  1996, 11(4), 247-254.
[http://dx.doi.org/10.1097/00004850-199612000-00006] [PMID:  9031991] 
[26] 
Phillips, K.A. An open-label study of escitalopram in body dysmorphic disorder. Int. Clin. Psychopharmacol.,  2006, 21(3), 177-179.
[http://dx.doi.org/10.1097/01.yic.0000194378.65460.ef] [PMID:  16528140] 
[27] 
Phillips, K.A.; Najjar, F. An open-label study of citalopram in body dysmorphic disorder. J. Clin. Psychiatry,  2003, 64(6), 715-720.
[http://dx.doi.org/10.4088/JCP.v64n0615] [PMID:  12823088] 
[28] 
Phillips, K.A.; Albertini, R.S.; Rasmussen, S.A. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch. Gen. Psychiatry,  2002, 59(4), 381-388.
[http://dx.doi.org/10.1001/archpsyc.59.4.381] [PMID:  11926939] 
[29] 
Phillips, K.A.; Keshaviah, A.; Dougherty, D.D.; Stout, R.L.; Menard, W.; Wilhelm, S. Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. Am. J. Psychiatry,  2016, 173(9), 887-895.
[http://dx.doi.org/10.1176/appi.ajp.2016.15091243] [PMID:  27056606] 
[30] 
Phillips, K.A.; Dwight, M.M.; McElroy, S.L. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J. Clin. Psychiatry,  1998, 59(4), 165-171.
[http://dx.doi.org/10.4088/JCP.v59n0404] [PMID:  9590666] 
[31] 
Stasi, C.; Caserta, A.; Nisita, C.; Cortopassi, S.; Fani, B.; Salvadori, S.; Pancetti, A.; Bertani, L.; Gambaccini, D.; de Bortoli, N.; Dell’Osso, L.; Blandizzi, C.; Marchi, S.; Bellini, M. The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. J. Gastroenterol. Hepatol.,  2019, 34(4), 713-719.
[http://dx.doi.org/10.1111/jgh.14375] [PMID:  29971822] 
[32] 
Tadyon, N.B. Therapeutic effects of saffron (Crocus sativus) versus fluoxetine on Irritable Bowel Syndrome: A double-blind randomized clinical trial. Adv. Integr. Med.,  2019, 6(4), 167-173.
[http://dx.doi.org/10.1016/j.aimed.2019.01.001] 
[33] 
Abu El-Hamd, M.; Abdelhamed, A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia,  2018, 50(1), 12829.
[http://dx.doi.org/10.1111/and.12829] [PMID:  28497478] 
[34] 
Akgül, T.; Karakan, T.; Ayyildiz, A.; Germiyanoğlu, C. Comparison of sertraline and citalopram for treatment of premature ejaculation. Urol. J.,  2008, 5(1), 41-45.
[PMID:  18454426] 
[35] 
Atmaca, M.; Kuloglu, M.; Tezcan, E.; Semercioz, A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int. J. Impot. Res.,  2002, 14(6), 502-505.
[http://dx.doi.org/10.1038/sj.ijir.3900918] [PMID:  12494286] 
[36] 
Balci, M.; Atan, A.; Senel, C.; Guzel, O.; Aslan, Y.; Lokman, U.; Kayali, M.; Bilgin, O. Comparison of the treatment efficacies of paroxetine, fluoxetine and dapoxetine in low socioeconomic status patients with lifelong premature ejaculation. Cent. Eur J. Urol.,  2019, 72(2), 185-190.
[PMID:  31482028] 
[37] 
Gameel, T.A.; Tawfik, A.M.; Abou-Farha, M.O.; Bastawisy, M.G.; El-Bendary, M.A. El-Gamasy, Ael-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: A randomised placebo-controlled clinical trial. Arab J. Urol.,  2013, 11(4), 392-397.
[http://dx.doi.org/10.1016/j.aju.2013.05.003] [PMID:  26558110] 
[38] 
Gong, Z.Y.; Tang, T.L.; Cui, S.; Wang, J.Z.; Deng, X.Z. Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue,  2011, 17(10), 923-925.
[PMID:  22049798] 
[39] 
Haensel, S.M.; Klem, T.M.; Hop, W.C.; Slob, A.K. Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J. Clin. Psychopharmacol.,  1998, 18(1), 72-77.
[http://dx.doi.org/10.1097/00004714-199802000-00012] [PMID:  9472846] 
[40] 
Hamidi-Madani, A.; Motiee, R.; Mokhtari, G.; Nasseh, H.; Esmaeili, S.; Kazemnezhad, E. The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: A randomized double-blind placebo-controlled clinical trial. J. Reprod. Infertil.,  2018, 19(1), 10-15.
[PMID:  29850442] 
[41] 
Hosseini, M.M.; Yarmohammadi, H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol. Int.,  2007, 79(1), 28-32.
[http://dx.doi.org/10.1159/000102909] [PMID:  17627164] 
[42] 
Jenkins, L.C.; Gonzalez, J.; Tal, R.; Guhring, P.; Parker, M.; Mulhall, J.P. Compliance with fluoxetine use in men with primary premature ejaculation. J. Sex. Med.,  2019, 16(12), 1895-1899.
[http://dx.doi.org/10.1016/j.jsxm.2019.09.017] [PMID:  31735615] 
[43] 
Kara, H.; Aydin, S.; Yücel, M.; Agargün, M.Y.; Odabaş, O.; Yilmaz, Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J. Urol.,  1996, 156(5), 1631-1632.
[http://dx.doi.org/10.1016/S0022-5347(01)65467-3] [PMID:  8863556] 
[44] 
Kim, S.C.; Seo, K.K. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J. Urol.,  1998, 159(2), 425-427.
[http://dx.doi.org/10.1016/S0022-5347(01)63940-5] [PMID:  9649255] 
[45] 
Madeo, B.; Bettica, P.; Milleri, S.; Balestrieri, A.; Granata, A.R.; Carani, C.; Rochira, V. The effects of citalopram and fluoxetine on sexual behavior in healthy men: evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebo-controlled, double-blind, double-dummy, parallel group study. J. Sex. Med.,  2008, 5(10), 2431-2441.
[http://dx.doi.org/10.1111/j.1743-6109.2008.00843.x] [PMID:  18410297] 
[46] 
Manasia, P.; Pomerol, J.; Ribè, N.; Gutierrez del Pozo, R.; Alcover Garcia, J. Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation. J. Urol.,  2003, 170(1), 164-165.
[http://dx.doi.org/10.1097/01.ju.0000071040.12407.32] [PMID:  12796671] 
[47] 
Mattos, R.M.; Marmo Lucon, A.; Srougi, M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol. Int.,  2008, 80(2), 162-165.
[http://dx.doi.org/10.1159/000112607] [PMID:  18362486] 
[48] 
Nada, E.A. A Comparison between citalopram and escitalopram in treatment of patients with premature ejaculation: a double-blind controlled clinical study. J. Sex. Med.,  2012, 9, 261-262.
[49] 
Nada, E.; Saleh, R.; Abu, M. The use of Escitalopram in treatment of patients with premature ejaculation: A randomized, double-blind, placebo-controlled study. J. Sex. Med.,  2009, 6.
[50] 
Novaretti, J.P.T.; Pompeo, A.; Arap, S. Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. Br. J. Urol.,  2002, 28(2), 116-122.
[51] 
Rezakhaniha, B.; Sirosbakht, S. Efficacy of selective serotonin reuptake inhibitor (SSRI) in patient with premature ejaculation. Iran. J. Reprod. Med.,  2010, 8(2), 55-59.
[52] 
Safarinejad, M.R. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin. Neuropharmacol.,  2006, 29(5), 243-252.
[http://dx.doi.org/10.1097/01.WNF.0000228210.12194.46] [PMID:  16960468] 
[53] 
Safarinejad, M.R. Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J. Clin. Psychopharmacol.,  2007, 27(5), 444-450.
[http://dx.doi.org/10.1097/jcp.0b013e31814b98d4] [PMID:  17873675] 
[54] 
Safarinejad, M.R.; Hosseini, S.Y. Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int. J. Impot. Res.,  2006, 18(2), 164-169.
[http://dx.doi.org/10.1038/sj.ijir.3901384] [PMID:  16107866] 
[55] 
Sunay, D.; Sunay, M.; Aydoğmuş, Y.; Bağbancı, S.; Arslan, H.; Karabulut, A.; Emir, L. Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. Eur. Urol.,  2011, 59(5), 765-771.
[http://dx.doi.org/10.1016/j.eururo.2011.01.019] [PMID:  21256670] 
[56] 
Vahid, F. On-demand treatment of premature ejaculation with citalopram: A Randomized double-blind study. Acta Med. Iran.,  2009, 47(5), 353-357.
[57] 
Waldinger, M.D.; Hengeveld, M.W.; Zwinderman, A.H.; Olivier, B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J. Clin. Psychopharmacol.,  1998, 18(4), 274-281.
[http://dx.doi.org/10.1097/00004714-199808000-00004] [PMID:  9690692] 
[58] 
Waldinger, M.D.; Zwinderman, A.H.; Olivier, B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J. Clin. Psychopharmacol.,  2001, 21(3), 293-297.
[http://dx.doi.org/10.1097/00004714-200106000-00007] [PMID:  11386492] 
[59] 
Yilmaz, U.; Tatlişen, A.; Turan, H.; Arman, F.; Ekmekçioğlu, O. The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. J. Urol.,  1999, 161(1), 107-111.
[http://dx.doi.org/10.1016/S0022-5347(01)62078-0] [PMID:  10037380] 
[60] 
Coleman, E. An exploratory study of the role of psychotropic medications in the treatment of sex offenders. J. Offender Rehabil.,  1992, 18(3-4), 75-88.
[http://dx.doi.org/10.1300/J076v18n03_08] 
[61] 
Greenberg, D.M.; Bradford, J.M.; Curry, S.; O’Rourke, A. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull. Am. Acad. Psychiatry Law,  1996, 24(4), 525-532.
[PMID:  9001750] 
[62] 
Kafka, M.P. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann. Clin. Psychiatry,  1994, 6(3), 189-195.
[http://dx.doi.org/10.3109/10401239409149003] [PMID:  7881500] 
[63] 
Kafka, M.P. Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. J. Clin. Psychiatry,  1991, 52(2), 60-65.
[PMID:  1993637] 
[64] 
Kafka, M.P.; Hennen, J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J. Clin. Psychiatry,  2000, 61(9), 664-670.
[http://dx.doi.org/10.4088/JCP.v61n0912] [PMID:  11030487] 
[65] 
Kafka, M.P.; Prentky, R. A comparative study of nonparaphilic sexual addictions and paraphilias in men. J. Clin. Psychiatry,  1992, 53(10), 345-350.
[PMID:  1429473] 
[66] 
Kafka, M.P.; Prentky, R. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J. Clin. Psychiatry,  1992, 53(10), 351-358.
[PMID:  1429474] 
[67] 
Kraus, C.; Strohm, K.; Hill, A.; Habermann, N.; Berner, W.; Briken, P. Selective serotonine reuptake inhibitors (SSRI) in the treatment of paraphilia. Fortschr. Neurol. Psychiatr.,  2007, 75(6), 351-356.
[http://dx.doi.org/10.1055/s-2006-944261] [PMID:  17031776] 
[68] 
Stein, D.J.; Hollander, E.; Anthony, D.T.; Schneier, F.R.; Fallon, B.A.; Liebowitz, M.R.; Klein, D.F. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J. Clin. Psychiatry,  1992, 53(8), 267-271.
[PMID:  1386848] 
[69] 
LaCroix, A.Z.; Freeman, E.W.; Larson, J.; Carpenter, J.S.; Joffe, H.; Reed, S.D.; Newton, K.M.; Seguin, R.A.; Sternfeld, B.; Cohen, L.; Ensrud, K.E. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas,  2012, 73(4), 361-368.
[http://dx.doi.org/10.1016/j.maturitas.2012.09.006] [PMID:  23031421] 
[70] 
Barton, D.L.; LaVasseur, B.I.; Sloan, J.A.; Stawis, A.N.; Flynn, K.A.; Dyar, M.; Johnson, D.B.; Atherton, P.J.; Diekmann, B.; Loprinzi, C.L. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J. Clin. Oncol.,  2010, 28(20), 3278-3283.
[http://dx.doi.org/10.1200/JCO.2009.26.6379] [PMID:  20498389] 
[71] 
Flevari, P.; Leftheriotis, D.; Repasos, E.; Katsaras, D.; Katsimardos, A.; Lekakis, J. Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. Europace,  2017, 19(1), 127-131.
[http://dx.doi.org/10.1093/europace/euw153] [PMID:  27702846] 
[72] 
Kadri, A.N.; Nusairat, L.; Kadri, S.; Alqaid, A.; Hernandez, A.V.; Kadri, N.N. Effect of citalopram for the treatment of neurocardiogenic syncope. Am. J. Ther.,  2019, 26(3), e339-e343.
[http://dx.doi.org/10.1097/MJT.0000000000000652] [PMID:  28816725] 
[73] 
Coccaro, E.F.; Kavoussi, R.J. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch. Gen. Psychiatry,  1997, 54(12), 1081-1088.
[http://dx.doi.org/10.1001/archpsyc.1997.01830240035005] [PMID:  9400343] 
[74] 
Coccaro, E.F.; Kavoussi, R.J.; Hauger, R.L. Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol. Psychiatry,  1997, 42(7), 546-552.
[http://dx.doi.org/10.1016/S0006-3223(97)00309-0] [PMID:  9376450] 
[75] 
Coccaro, E.F.; Lee, R.J.; Kavoussi, R.J. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J. Clin. Psychiatry,  2009, 70(5), 653-662.
[http://dx.doi.org/10.4088/JCP.08m04150] [PMID:  19389333] 
[76] 
George, D.T.; Phillips, M.J.; Lifshitz, M.; Lionetti, T.A.; Spero, D.E.; Ghassemzedeh, N.; Doty, L.; Umhau, J.C.; Rawlings, R.R. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. J. Clin. Psychiatry,  2011, 72(1), 60-65.
[http://dx.doi.org/10.4088/JCP.09m05256gry] [PMID:  20673556] 
[77] 
Koran, L.M.; Aboujaoude, E.N.; Gamel, N.N. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J. Clin. Psychiatry,  2007, 68(3), 422-427.
[http://dx.doi.org/10.4088/JCP.v68n0311] [PMID:  17388713] 
[78] 
Lee, R.; Kavoussi, R.J.; Coccaro, E.F. Placebo-controlled, randomized trial of fluoxetine in the treatment of aggression in male intimate partner abusers. Int. Clin. Psychopharmacol.,  2008, 23(6), 337-341.
[http://dx.doi.org/10.1097/YIC.0b013e32830fbdd2] [PMID:  18854722] 
[79] 
Reist, C.; Nakamura, K.; Sagart, E.; Sokolski, K.N.; Fujimoto, K.A. Impulsive aggressive behavior: open-label treatment with citalopram. J. Clin. Psychiatry,  2003, 64(1), 81-85.
[http://dx.doi.org/10.4088/JCP.v64n0115] [PMID:  12590628] 
[80] 
Vartiainen, H.; Tiihonen, J.; Putkonen, A.; Koponen, H.; Virkkunen, M.; Hakola, P.; Lehto, H. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr. Scand.,  1995, 91(5), 348-351.
[http://dx.doi.org/10.1111/j.1600-0447.1995.tb09793.x] [PMID:  7639092] 
[81] 
Patetsos, E.; Horjales-Araujo, E. Treating Chronic Pain with SSRIs: What Do We Know? Pain Res. Manag.,  2016, 2016, 2020915.
[http://dx.doi.org/10.1155/2016/2020915] [PMID:  27445601] 
[82] 
Burch, R. Antidepressants for preventive treatment of migraine. Curr. Treat. Options Neurol.,  2019, 21(4), 18.
[http://dx.doi.org/10.1007/s11940-019-0557-2] [PMID:  30895388] 
[83] 
Bonilla, S.; Nurko, S. Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives. Clin. Exp. Gastroenterol.,  2018, 11, 365-372.
[http://dx.doi.org/10.2147/CEG.S146646] [PMID:  30310301] 
[84] 
Kułak-Bejda, A.; Bejda, G.; Waszkiewicz, N. Antidepressants for irritable bowel syndrome-A systematic review. Pharmacol. Rep.,  2017, 69(6), 1366-1379.
[http://dx.doi.org/10.1016/j.pharep.2017.05.014] [PMID:  29132094] 
[85] 
Du, Y.; Jiang, Y.; Zhang, J.; Tian, G.; Zhang, N.; Wu, D.; Bai, X. Efficacy and Safety of “On-Demand” dapoxetine in treatment of patients with premature ejaculation: A Meta-Analysis. Med. Sci. Monit.,  2019, 25, 4225-4232.
[http://dx.doi.org/10.12659/MSM.913606] [PMID:  31171764] 
[86] 
Jian, Z.; Wei, X.; Ye, D.; Li, H.; Wang, K. Pharmacotherapy of premature ejaculation: a systematic review and network meta-analysis. Int. Urol. Nephrol.,  2018, 50(11), 1939-1948.
[http://dx.doi.org/10.1007/s11255-018-1984-9] [PMID:  30225547] 
[87] 
Yi, Z.M.; Chen, S.D.; Tang, Q.Y.; Tang, H.L.; Zhai, S.D. Efficacy and safety of sertraline for the treatment of premature ejaculation: Systematic review and meta-analysis. Medicine (Baltimore),  2019, 98(23), e15989.
[http://dx.doi.org/10.1097/MD.0000000000015989] [PMID:  31169738] 
[88] 
Zhang, D.; Cheng, Y.; Wu, K.; Ma, Q.; Jiang, J.; Yan, Z. Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. BMC Urol.,  2019, 19(1), 2.
[http://dx.doi.org/10.1186/s12894-018-0431-7] [PMID:  30606186] 
[89] 
Riemma, G.; Schiattarella, A.; La Verde, M.; Zarobbi, G.; Garzon, S.; Cucinella, G.; Calagna, G.; Labriola, D.; De Franciscis, P. Efficacy of low-dose paroxetine for the treatment of hot flushes in surgical and physiological postmenopausal women: systematic review and meta-analysis of randomized trials. Medicina (Kaunas),  2019, 55(9), E554.
[http://dx.doi.org/10.3390/medicina55090554] [PMID:  31480427] 
[90] 
Abdel, F.M.R.; Jung, S.W.; Greenspan, M.A.; Padilla, M.; Enciso, R. Efficacy of antidepressants in the treatment of obstructive sleep apnea compared to placebo. a systematic review with meta-analysis. Sleep Breath.,  2020, 24(2), 443-453.
[http://dx.doi.org/10.1007/s11325-019-01954-9] [PMID:  31720982] 
[91] 
Legg, L.A.; Tilney, R.; Hsieh, C.F.; Wu, S.; Lundström, E.; Rudberg, A.S.; Kutlubaev, M.A.; Dennis, M.; Soleimani, B.; Barugh, A.; Hackett, M.L.; Hankey, G.J.; Mead, G.E. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst. Rev.,  2019, 2019(11), CD009286.
[http://dx.doi.org/10.1002/14651858.CD009286.pub3] [PMID:  31769878] 
[92] 
Hague, B.; Hall, J.; Kellett, S. Treatments for compulsive buying: A systematic review of the quality, effectiveness and progression of the outcome evidence. J. Behav. Addict.,  2016, 5(3), 379-394.
[http://dx.doi.org/10.1556/2006.5.2016.064] [PMID:  27640529] 
[93] 
Vos, T. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet,  2015, 386(9995), 743-800.
[http://dx.doi.org/10.1016/S0140-6736(15)60692-4] [PMID:  26063472] 
[94] 
Burch, R.C.; Buse, D.C.; Lipton, R.B. Migraine: epidemiology, burden, and comorbidity. Neurol. Clin.,  2019, 37(4), 631-649.
[http://dx.doi.org/10.1016/j.ncl.2019.06.001] [PMID:  31563224] 
[95] 
Charles, A. Migraine. N. Engl. J. Med.,  2017, 377(17), 1698-1699.
[http://dx.doi.org/10.1056/NEJMc1711803] [PMID:  29069565] 
[96] 
Huang, I.H.; Wu, P.C.; Lin, E.Y.; Chen, C.Y.; Kang, Y.N. Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials. Int. J. Mol. Sci.,  2019, 20(14), E3527.
[http://dx.doi.org/10.3390/ijms20143527] [PMID:  31323828] 
[97] 
Viganò, A.; Torrieri, M.C.; Toscano, M.; Puledda, F.; Petolicchio, B.; Sasso D’Elia, T.; Verzina, A.; Ruggiero, S.; Altieri, M.; Vicenzini, E.; Schoenen, J.; Di Piero, V. Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. J. Headache Pain,  2018, 19(1), 73.
[http://dx.doi.org/10.1186/s10194-018-0901-z] [PMID:  30128946] 
[98] 
Viganò, A.; Toscano, M.; Puledda, F.; Di Piero, V. Treating chronic migraine with neuromodulation: the role of neurophysiological abnormalities and maladaptive plasticity. Front. Pharmacol.,  2019, 10, 32.
[http://dx.doi.org/10.3389/fphar.2019.00032] [PMID:  30804782] 
[99] 
Deen, M.; Christensen, C.E.; Hougaard, A.; Hansen, H.D.; Knudsen, G.M.; Ashina, M. Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia,  2017, 37(3), 251-264.
[http://dx.doi.org/10.1177/0333102416640501] [PMID:  27013238] 
[100] 
Altamura, C.; Corbelli, I.; de Tommaso, M.; Di Lorenzo, C.; Di Lorenzo, G.; Di Renzo, A.; Filippi, M.; Jannini, T.B.; Messina, R.; Parisi, P.; Parisi, V.; Pierelli, F.; Rainero, I.; Raucci, U.; Rubino, E.; Sarchielli, P.; Li, L.; Vernieri, F.; Vollono, C.; Coppola, G. Pathophysiological bases of comorbidity in migraine. Front. Hum. Neurosci.,  2021, 15(131), 640574.
[http://dx.doi.org/10.3389/fnhum.2021.640574] [PMID:  33958992] 
[101] 
Saper, J.R.; Silberstein, S.D.; Lake, A.E., III; Winters, M.E. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache,  1994, 34(9), 497-502.
[http://dx.doi.org/10.1111/j.1526-4610.1994.hed3409497.x] [PMID:  8002320] 
[102] 
Saper, J.R.; Silberstein, S.D.; Lake, A.E., III; Winters, M.E. Fluoxetine and migraine: comparison of double-blind trials. Headache,  1995, 35(4), 233.
[http://dx.doi.org/10.1111/j.1526-4610.1995.hed3504233_1.x] [PMID:  7775182] 
[103] 
Black, K.J.; Sheline, Y.I. Paroxetine as migraine prophylaxis. J. Clin. Psychiatry,  1995, 56(7), 330-331.
[PMID:  7615489] 
[104] 
Hays, P. Paroxetine prevents migraines. J. Clin. Psychiatry,  1997, 58(1), 30-31.
[http://dx.doi.org/10.4088/JCP.v58n0106b] [PMID:  9055836] 
[105] 
Silberstein, S.D.; Holland, S.; Freitag, F.; Dodick, D.W.; Argoff, C.; Ashman, E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology,  2012, 78(17), 1337-1345.
[http://dx.doi.org/10.1212/WNL.0b013e3182535d20] [PMID:  22529202] 
[106] 
Alemdar, M.; Selekler, H.M. Migraine with aura triggered by citalopram. Neuropsychobiology,  2007, 55(2), 121-122.
[http://dx.doi.org/10.1159/000104469] [PMID:  17596740] 
[107] 
Bickel, A.; Kornhuber, J.; Maihöfner, C.; Ropohl, A. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline. A case report. Pharmacopsychiatry,  2005, 38(6), 327-328.
[http://dx.doi.org/10.1055/s-2005-916190] [PMID:  16342007] 
[108] 
Delva, N.J.; Horgan, S.A.; Hawken, E.R. Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors. Headache,  2000, 40(3), 248-251.
[http://dx.doi.org/10.1046/j.1526-4610.2000.00036.x] [PMID:  10759929] 
[109] 
Larson, E.W. Migraine with typical aura associated with fluoxetine therapy: case report. J. Clin. Psychiatry,  1993, 54(6), 235-236.
[PMID:  8331094] 
[110] 
Munera, P.A.; Goldstein, A. Migraine and sertraline. J. Am. Acad. Child Adolesc. Psychiatry,  2001, 40(10), 1125-1126.
[http://dx.doi.org/10.1097/00004583-200110000-00005] [PMID:  11589524] 
[111] 
Mufaddel, A.; Osman, O.T.; Almugaddam, F.; Jafferany, M. A review of body dysmorphic disorder and its presentation in different clinical settings. . Prim. Care Companion CNS Disord.,  2013, 15(4)PCC.12r01464. 
[http://dx.doi.org/10.4088/PCC.12r01464] [PMID:  24392251] 
[112] 
Mancuso, S.G.; Knoesen, N.P.; Castle, D.J. Delusional versus nondelusional body dysmorphic disorder. Compr. Psychiatry,  2010, 51(2), 177-182.
[http://dx.doi.org/10.1016/j.comppsych.2009.05.001] [PMID:  20152299] 
[113] 
Krebs, G.; Fernández de la Cruz, L.; Monzani, B.; Bowyer, L.; Anson, M.; Cadman, J.; Heyman, I.; Turner, C.; Veale, D.; Mataix-Cols, D. Long-term outcomes of cognitive-behavioral therapy for adolescent body dysmorphic disorder. Behav. Ther.,  2017, 48(4), 462-473.
[http://dx.doi.org/10.1016/j.beth.2017.01.001] [PMID:  28577583] 
[114] 
Veale, D.; Anson, M.; Miles, S.; Pieta, M.; Costa, A.; Ellison, N. Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: a randomised controlled trial. Psychother. Psychosom.,  2014, 83(6), 341-353.
[http://dx.doi.org/10.1159/000360740] [PMID:  25323062] 
[115] 

 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed; American Psychiatric Association Publishing: Washington, DC, 2013. 
[116] 
New, A.S.; Buchsbaum, M.S.; Hazlett, E.A.; Goodman, M.; Koenigsberg, H.W.; Lo, J.; Iskander, L.; Newmark, R.; Brand, J.; O’Flynn, K.; Siever, L.J. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl.),  2004, 176(3-4), 451-458.
[http://dx.doi.org/10.1007/s00213-004-1913-8] [PMID:  15160265] 
[117] 
Coccaro, E.F. Central serotonin and impulsive aggression. Br. J. Psychiatry Suppl.,  1989, (8), 52-62.
[http://dx.doi.org/10.1192/S0007125000291769] [PMID:  2692640] 
[118] 
Toscano, M.; Viganò, A.; Puledda, F.; Verzina, A.; Rocco, A.; Lenzi, G.L.; Di Piero, V. Serotonergic correlation with anger and aggressive behavior in acute stroke patients: an intensity dependence of auditory evoked potentials (IDAP) study. Eur. Neurol.,  2014, 72(3-4), 186-192.
[http://dx.doi.org/10.1159/000362268] [PMID:  25227246] 
[119] 
van der Vegt, B.J.; Lieuwes, N.; Cremers, T.I.; de Boer, S.F.; Koolhaas, J.M. Cerebrospinal fluid monoamine and metabolite concentrations and aggression in rats. Horm. Behav.,  2003, 44(3), 199-208.
[http://dx.doi.org/10.1016/S0018-506X(03)00132-6] [PMID:  14609542] 
[120] 
Chong, S.A.; Low, B.L. Treatment of kleptomania with fluvoxamine. Acta Psychiatr. Scand.,  1996, 93(4), 314-315.
[http://dx.doi.org/10.1111/j.1600-0447.1996.tb10654.x] [PMID:  8712034] 
[121] 
Kraus, J.E. Treatment of kleptomania with paroxetine. J. Clin. Psychiatry,  1999, 60(11), 793.
[http://dx.doi.org/10.4088/JCP.v60n1116] [PMID:  10584771] 
[122] 
Mayer, E.A. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med.,  2008, 358(16), 1692-1699.
[http://dx.doi.org/10.1056/NEJMcp0801447] [PMID:  18420501] 
[123] 
Drossman, D.A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and rome IV. Gastroenterology,,  2016, S0016-5085(16), 00223-7.
[http://dx.doi.org/10.1053/j.gastro.2016.02.032] [PMID:  27144617] 
[124] 
Mozaffari, S.; Nikfar, S.; Abdollahi, M. The safety of novel drugs used to treat irritable bowel syndrome. Expert Opin. Drug Saf.,  2014, 13(5), 625-638.
[http://dx.doi.org/10.1517/14740338.2014.902932] [PMID:  24669839] 
[125] 
Noorafshan, A.; Yousefi, M.; Hosseini, L.; Karbalay-Doust, S. Can sertraline and nortriptyline protect the neurons in submucosal and myenteric plexuses of Rat’s Colon Against Stress? Dig. Dis. Sci.,  2019, 64(9), 2548-2554.
[http://dx.doi.org/10.1007/s10620-019-05600-y] [PMID:  30937720] 
[126] 
Stasi, C.; Bellini, M.; Bassotti, G.; Blandizzi, C.; Milani, S. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech. Coloproctol.,  2014, 18(7), 613-621.
[http://dx.doi.org/10.1007/s10151-013-1106-8] [PMID:  24425100] 
[127] 
Lin, W-T.; Liao, Y.J.; Peng, Y.C.; Chang, C.H.; Lin, C.H.; Yeh, H.Z.; Chang, C.S. Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study. World J. Gastroenterol.,  2017, 23(19), 3513-3521.
[http://dx.doi.org/10.3748/wjg.v23.i19.3513] [PMID:  28596687] 
[128] 
Thibaut, F.; Cosyns, P.; Fedoroff, J.P.; Briken, P.; Goethals, K.; Bradford, J.M.W. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. World J. Biol. Psychiatry,  2020, 21(6), 412-490.
[http://dx.doi.org/10.1080/15622975.2020.1744723] [PMID:  32452729] 
[129] 
Snoeren, E.M.S.; Veening, J.G.; Olivier, B.; Oosting, R.S. Serotonin 1A receptors and sexual behavior in male rats: a review. Pharmacol. Biochem. Behav.,  2014, 121, 102-114.
[http://dx.doi.org/10.1016/j.pbb.2013.11.007] [PMID:  24239787] 
[130] 
Turner, D.; Schöttle, D.; Bradford, J.; Briken, P. Assessment methods and management of hypersexuality and paraphilic disorders. Curr. Opin. Psychiatry,  2014, 27(6), 413-422.
[http://dx.doi.org/10.1097/YCO.0000000000000099] [PMID:  25247453] 
[131] 
Fontanesi, L. Hypersexuality and Trauma: a mediation and moderation model from psychopathology to problematic sexual behavior. J. Affect. Disord.,  2020, 281, 631-637.
[PMID:  33229025] 
[132] 
Björkholm, C.; Monteggia, L.M. BDNF - a key transducer of antidepressant effects. Neuropharmacology,  2016, 102, 72-79.
[http://dx.doi.org/10.1016/j.neuropharm.2015.10.034] [PMID:  26519901] 
[133] 
Casarotto, P.C. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell,  2021, 184(5), 1299-1313.
[134] 
Bourgeois, J.A.; Klein, M. Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J. Clin. Psychopharmacol.,  1996, 16(3), 257-258.
[http://dx.doi.org/10.1097/00004714-199606000-00015] [PMID:  8784662] 
[135] 
Perilstein, R.D.; Lipper, S.; Friedman, L.J. Three cases of paraphilias responsive to fluoxetine treatment. J. Clin. Psychiatry,  1991, 52(4), 169-170.
[PMID:  2016251] 
[136] 
Bianchi, M.D. Fluoxetine treatment of exhibitionism. Am. J. Psychiatry,  1990, 147(8), 1089-1090.
[http://dx.doi.org/10.1176/ajp.147.8.1089c] [PMID:  2375447] 
[137] 
Yang, F.W.; Liang, C.S. Paraphilias in schizophrenia: differential diagnosis and treatment with selective serotonin reuptake inhibitors. Prog. Neuropsychopharmacol. Biol. Psychiatry,  2010, 34(6), 1126-1127.
[http://dx.doi.org/10.1016/j.pnpbp.2010.04.012] [PMID:  20403404] 
[138] 
Lorefice, L.S. Fluoxetine treatment of a fetish. J. Clin. Psychiatry,  1991, 52(1), 41.
[PMID:  1988418] 
[139] 
Emmanuel, N.P.; Lydiard, R.B.; Ballenger, J.C. Fluoxetine treatment of voyeurism. Am. J. Psychiatry,  1991, 148(7), 950.
[http://dx.doi.org/10.1176/ajp.148.7.950a] [PMID:  2053642] 
[140] 
Bhatia, M.S.; Jhanjee, A.; Srivastava, S.; Kumar, P. An uncommon case of hypersexual behaviour with frotteurism. Med. Sci. Law,  2010, 50(4), 228-229.
[http://dx.doi.org/10.1258/msl.2010.010103] [PMID:  21539293] 
[141] 
Aguirre, B. Fluoxetine and compulsive sexual behavior. J. Am. Acad. Child Adolesc. Psychiatry,  1999, 38(8), 943-943.
[http://dx.doi.org/10.1097/00004583-199908000-00008] [PMID:  10434484] 
[142] 
Galli, V.B.; Raute, N.J.; McConville, B.J.; McElroy, S.L. An adolescent male with multiple paraphilias successfully treated with fluoxetine. J. Child Adolesc. Psychopharmacol.,  1998, 8(3), 195-197.
[http://dx.doi.org/10.1089/cap.1998.8.195] [PMID:  9853694] 
[143] 
Bradford, J.M.; Gratzer, T.G. A treatment for impulse control disorders and paraphilia: a case report. Can. J. Psychiatry,  1995, 40(1), 4-5.
[http://dx.doi.org/10.1177/070674379504000103] [PMID:  7874674] 
[144] 
Chow, E.W.C.; Choy, A.L. Clinical characteristics and treatment response to SSRI in a female pedophile. Arch. Sex. Behav.,  2002, 31(2), 211-215.
[http://dx.doi.org/10.1023/A:1014795321404] [PMID:  11974646] 
[145] 
Rubenstein, E.B.; Engel, N.L. Successful treatment of transvestic fetishism with sertraline and lithium. J. Clin. Psychiatry,  1996, 57(2), 92.
[PMID:  8591978] 
[146] 
Cetin, F.H. Inappropriate sexual behaviors associated with mental retardation or transvestic fetishism: a case study. Anadolu Psikiyatri Dergisi-Anatolian J. Psychiat.,  2015, 16(6), 454-457.
[http://dx.doi.org/10.5455/apd.1414665797] 
[147] 
Patra, A.P.; Bharadwaj, B.; Shaha, K.K.; Das, S.; Rayamane, A.P.; Tripathi, C.S. Impulsive frotteurism: a case report. Med. Sci. Law,  2013, 53(4), 235-238.
[http://dx.doi.org/10.1177/0025802412474813] [PMID:  23929674] 
[148] 
Ismail, N.; Husain, R.; Sidi, H. Anxiety-depression psychopathology of a patient with voyeurism, major depression and premature ejaculation. Asian J. Psychiatr.,  2017, 18(2), 278-280.
[149] 
Zohar, J.; Kaplan, Z.; Benjamin, J. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J. Clin. Psychiatry,  1994, 55(3), 86-88.
[PMID:  8071253] 
[150] 
Stewart, J.T.; Shin, K.J. Paroxetine treatment of sexual disinhibition in dementia. Am. J. Psychiatry,  1997, 154(10), 1474.
[http://dx.doi.org/10.1176/ajp.154.10.1474a] [PMID:  9326839] 
[151] 
Abouesh, A.; Clayton, A. Compulsive voyeurism and exhibitionism: a clinical response to paroxetine. Arch. Sex. Behav.,  1999, 28(1), 23-30.
[http://dx.doi.org/10.1023/A:1018737504537] [PMID:  10097802] 
[152] 
Wainberg, M.L.; Muench, F.; Morgenstern, J.; Hollander, E.; Irwin, T.W.; Parsons, J.T.; Allen, A.; O’Leary, A. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J. Clin. Psychiatry,  2006, 67(12), 1968-1973.
[http://dx.doi.org/10.4088/JCP.v67n1218] [PMID:  17194276] 
[153] 
Haverkos, H.W.; Drotman, D.P. The social organization of sexuality. JAMA,  1995, 274(7), 535-537.
[http://dx.doi.org/10.1001/jama.274.7.535] [PMID:  7629977] 
[154] 
Mazza, M.; Harnic, D.; Catalano, V.; Di Nicola, M.; Bruschi, A.; Bria, P.; Daniele, A.; Mazza, S. Sexual behavior in women with bipolar disorder. J. Affect. Disord.,  2011, 131(1-3), 364-367.
[http://dx.doi.org/10.1016/j.jad.2010.11.010] [PMID:  21130498] 
[155] 
Nordvig, A.S.; Goldberg, D.J.; Huey, E.D.; Miller, B.L. The cognitive aspects of sexual intimacy in dementia patients: a neurophysiological review. Neurocase,  2019, 25(1-2), 66-74.
[http://dx.doi.org/10.1080/13554794.2019.1603311] [PMID:  30990123] 
[156] 
Schöttle, D.; Briken, P.; Tüscher, O.; Turner, D. Sexuality in autism: hypersexual and paraphilic behavior in women and men with high-functioning autism spectrum disorder. Dialogues Clin. Neurosci.,  2017, 19(4), 381-393.
[http://dx.doi.org/10.31887/DCNS.2017.19.4/dschoettle] [PMID:  29398933] 
[157] 
Estellon, V.; Mouras, H. Sexual addiction: insights from psychoanalysis and functional neuroimaging. Socioaffect. Neurosci. Psychol.,  2012, 2, 11814.
[http://dx.doi.org/10.3402/snp.v2i0.11814] [PMID:  24693342] 
[158] 
Anneser, J.M.; Jox, R.J.; Borasio, G.D. Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph. Lateral Scler.,  2007, 8(3), 189-190.
[http://dx.doi.org/10.1080/17482960601073543] [PMID:  17538783] 
[159] 
Herguner, S.; Herguner, A.; Cicek, E. Combination of risperidone and paroxetine for inappropriate sexual behaviors in an adolescent with autism and mental retardation. Noropsikiyatri Arsivi-Arch. Neuropsychiatry,  2012, 49(4), 311-313.
[160] 
Malladi, S.S.; Singh, A.N. Hypersexuality and its response to citalopram in a patient with hypothalamic hamartoma and precocious puberty. Int. J. Neuropsychopharmacol.,  2005, 8(4), 635-636.
[http://dx.doi.org/10.1017/S1461145705005493] [PMID:  15927088] 
[161] 
Ozmen, M.; Erdogan, A.; Duvenci, S.; Ozyurt, E.; Ozkara, C. Excessive masturbation after epilepsy surgery. Epilepsy Behav.,  2004, 5(1), 133-136.
[http://dx.doi.org/10.1016/j.yebeh.2003.10.009] [PMID:  14751219] 
[162] 
Raymond, N.C.; Grant, J.E.; Kim, S.W.; Coleman, E. Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: two case studies. Int. Clin. Psychopharmacol.,  2002, 17(4), 201-205.
[http://dx.doi.org/10.1097/00004850-200207000-00008] [PMID:  12131605] 
[163] 
Schupak, C. Case report: lamotrigine/fluoxetine combination in the treatment of compulsive sexual behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry,  2007, 31(6), 1337-1338.
[http://dx.doi.org/10.1016/j.pnpbp.2007.04.011] [PMID:  17630065] 
[164] 
Solanki, M.S.; Singh, P. Right thalamic bleed resulting in hypersexuality successfully treated with Selective Serotonin reuptake inhibitor Sertraline - A case report. Asian J. Psychiatr.,  2017, 30, 210-211.
[http://dx.doi.org/10.1016/j.ajp.2017.10.030] [PMID:  29132063] 
[165] 
Tosto, G.; Talarico, G.; Lenzi, G.L.; Bruno, G. Effect of citalopram in treating hypersexuality in an Alzheimer’s disease case. Neurol. Sci.,  2008, 29(4), 269-270.
[http://dx.doi.org/10.1007/s10072-008-0979-1] [PMID:  18810603] 
[166] 
Kornreich, C.; Den Dulk, A.; Verbanck, P.; Pelc, I. Fluoxetine treatment of compulsive masturbation in a schizophrenic patient. J. Clin. Psychiatry,  1995, 56(7), 334-334.
[PMID:  7615493] 
[167] 
Rao, V.; Handel, S.; Vaishnavi, S.; Keach, S.; Robbins, B.; Spiro, J.; Ward, J.; Berlin, F. Psychiatric sequelae of traumatic brain injury: a case report. Am. J. Psychiatry,  2007, 164(5), 728-735.
[http://dx.doi.org/10.1176/ajp.2007.164.5.728] [PMID:  17475730] 
[168] 
Stein, D.J.; Black, D.W.; Shapira, N.A.; Spitzer, R.L. Hypersexual disorder and preoccupation with internet pornography. Am. J. Psychiatry,  2001, 158(10), 1590-1594.
[http://dx.doi.org/10.1176/appi.ajp.158.10.1590] [PMID:  11578986] 
[169] 
Jannini, E.A.; Lenzi, A. Epidemiology of premature ejaculation. Curr. Opin. Urol.,  2005, 15(6), 399-403.
[http://dx.doi.org/10.1097/01.mou.0000182327.79572.fd] [PMID:  16205491] 
[170] 
Jannini, E.A.; Ciocca, G.; Limoncin, E.; Mollaioli, D.; Di Sante, S.; Gianfrilli, D.; Lombardo, F.; Lenzi, A. Premature ejaculation: old story, new insights. Fertil. Steril.,  2015, 104(5), 1061-1073.
[http://dx.doi.org/10.1016/j.fertnstert.2015.08.035] [PMID:  26409323] 
[171] 
Sansone, A. Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS). J. Endocrinol. Invest., 2020.
[http://dx.doi.org/10.1007/s40618-020-01458-4] [PMID:  33128158] 
[172] 
Althof, S.E.; Abdo, C.H.; Dean, J.; Hackett, G.; McCabe, M.; McMahon, C.G.; Rosen, R.C.; Sadovsky, R.; Waldinger, M.; Becher, E.; Broderick, G.A.; Buvat, J.; Goldstein, I.; El-Meliegy, A.I.; Giuliano, F.; Hellstrom, W.J.; Incrocci, L.; Jannini, E.A.; Park, K.; Parish, S.; Porst, H.; Rowland, D.; Segraves, R.; Sharlip, I.; Simonelli, C.; Tan, H.M. International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J. Sex. Med.,  2010, 7(9), 2947-2969.
[http://dx.doi.org/10.1111/j.1743-6109.2010.01975.x] [PMID:  21050394] 
[173] 
McMahon, C.G.; Jannini, E.; Waldinger, M.; Rowland, D. Standard operating procedures in the disorders of orgasm and ejaculation. J. Sex. Med.,  2013, 10(1), 204-229.
[http://dx.doi.org/10.1111/j.1743-6109.2012.02824.x] [PMID:  22970767] 
[174] 
Ciocca, G.; Limoncin, E.; Mollaioli, D.; Gravina, G.L.; Di Sante, S.; Carosa, E.; Lenzi, A.; Jannini, E.A. Integrating psychotherapy and pharmacotherapy in the treatment of premature ejaculation. Arab J. Urol.,  2013, 11(3), 305-312.
[http://dx.doi.org/10.1016/j.aju.2013.04.011] [PMID:  26558097] 
[175] 
Abdel-Hamid, I.A.; Jannini, E.A.; Andersson, K.E. Premature ejaculation: focus on therapeutic targets. Expert Opin. Ther. Targets,  2009, 13(2), 175-193.
[http://dx.doi.org/10.1517/14728220802663549] [PMID:  19236236] 
[176] 
Forster, P.; King, J. Fluoxetine for premature ejaculation. Am. J. Psychiatry,  1994, 151(10), 1523.
[http://dx.doi.org/10.1176/ajp.151.10.1523a] [PMID:  8092349] 
[177] 
Waldinger, M.D.; Zwinderman, A.H.; Olivier, B. SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J. Clin. Psychopharmacol.,  2001, 21(6), 556-560.
[http://dx.doi.org/10.1097/00004714-200112000-00003] [PMID:  11763001] 
[178] 
Kalejaiye, O.; Almekaty, K.; Blecher, G.; Minhas, S. Premature ejaculation: challenging new and the old concepts. F1000 Res.,  2017, 6, 2084.
[http://dx.doi.org/10.12688/f1000research.12150.1] [PMID:  29259775] 
[179] 
Colonnello, E. Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity. Nat. Rev. Urol.,  2021, 18(2), 115-127.
[PMID:  33442049] 
[180] 
Howes, O.D.; Rogdaki, M.; Findon, J.L.; Wichers, R.H.; Charman, T.; King, B.H.; Loth, E.; McAlonan, G.M.; McCracken, J.T.; Parr, J.R.; Povey, C.; Santosh, P.; Wallace, S.; Simonoff, E.; Murphy, D.G. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J. Psychopharmacol.,  2018, 32(1), 3-29.
[http://dx.doi.org/10.1177/0269881117741766] [PMID:  29237331] 
[181] 
Mika, J.; Zychowska, M.; Makuch, W.; Rojewska, E.; Przewlocka, B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol. Rep.,  2013, 65(6), 1611-1621.
[http://dx.doi.org/10.1016/S1734-1140(13)71522-6] [PMID:  24553009] 
[182] 
Fitzcharles, M.A.; Ste-Marie, P.A.; Goldenberg, D.L.; Pereira, J.X.; Abbey, S.; Choinière, M.; Ko, G.; Moulin, D.E.; Panopalis, P.; Proulx, J.; Shir, Y. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res. Manag.,  2013, 18(3), 119-126.
[http://dx.doi.org/10.1155/2013/918216] [PMID:  23748251] 
[183] 
El-Solh, A.A. Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat. Sci. Sleep,  2018, 10, 409-420.
[http://dx.doi.org/10.2147/NSS.S166089] [PMID:  30538593] 
[184] 
Stoffers-Winterling, J.; Storebø, O.J.; Lieb, K. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr. Psychiatry Rep.,  2020, 22(8), 37.
[http://dx.doi.org/10.1007/s11920-020-01164-1] [PMID:  32504127] 
[185] 
Mayer, L.E.; Walsh, B.T. The use of selective serotonin reuptake inhibitors in eating disorders. J. Clin. Psychiatry,  1998, 59(Suppl. 15), 28-34.
[PMID:  9786308] 
[186] 
Milano, W.; De Rosa, M.; Milano, L.; Capasso, A. Night eating syndrome: an overview. J. Pharm. Pharmacol.,  2012, 64(1), 2-10.
[http://dx.doi.org/10.1111/j.2042-7158.2011.01353.x] [PMID:  22150667] 
[187] 
Bianciardi, E.; Di Lorenzo, G.; Niolu, C.; Betrò, S.; Zerbin, F.; Gentileschi, P.; Siracusano, A. Body image dissatisfaction in individuals with obesity seeking bariatric surgery: exploring the burden of new mediating factors. Riv. Psichiatr.,  2019, 54(1), 8-17.
[PMID:  30760932] 
[188] 
Bianciardi, E.; Fabbricatore, M.; Di Lorenzo, G.; Innamorati, M.; Tomassini, L.; Gentileschi, P.; Niolu, C.; Siracusano, A.; Imperatori, C. Prevalence of Food Addiction and Binge Eating in an Italian sample of bariatric surgery candidates and overweight/obese patients seeking low-energy-diet therapy. Riv. Psichiatr.,  2019, 54(3), 127-130.
[PMID:  31282493] 
[189] 
Vella, S.C.; Pai, N.B. A narrative review of potential treatment strategies for food addiction. Eat. Weight Disord.,  2017, 22(3), 387-393.
[http://dx.doi.org/10.1007/s40519-017-0400-2] [PMID:  28589470] 
[190] 
Sheikhpour, M. The current recommended drugs and strategies for the treatment of Coronavirus Disease (COVID-19). Ther. Clin. Risk Manag.,  2020, 16, 933-946.
[http://dx.doi.org/10.2147/TCRM.S262936] [PMID:  33116543] 
[191] 
Homolak, J.; Kodvanj, I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int. J. Antimicrob. Agents,  2020, 56(2), 106044.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106044] [PMID:  32522674] 
[192] 
Chen, H.; Reeves, J.H.; Fincham, J.E.; Kennedy, W.K.; Dorfman, J.H.; Martin, B.C. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J. Clin. Psychiatry,  2006, 67(6), 972-982.
[http://dx.doi.org/10.4088/JCP.v67n0615] [PMID:  16848658] 
[193] 
Walton, S.M.; Schumock, G.T.; Lee, K.V.; Alexander, G.C.; Meltzer, D.; Stafford, R.S. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy,  2008, 28(12), 1443-1452.
[http://dx.doi.org/10.1592/phco.28.12.1443] [PMID:  19025425] 
[194] 
Stone, K.J.; Viera, A.J.; Parman, C.L. Off-label applications for SSRIs. Am. Fam. Physician,  2003, 68(3), 498-504.
[PMID:  12924832] 
[195] 
Chen, D.T.; Wynia, M.K.; Moloney, R.M.; Alexander, G.C.U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol. Drug Saf.,  2009, 18(11), 1094-1100.
[http://dx.doi.org/10.1002/pds.1825] [PMID:  19697444] 
[196] 
Ghinea, N.; Lipworth, W.; Kerridge, I. Off-Label promotion of prescription medicine: is it ever justifiable? Ther. Innov. Regul. Sci.,  2015, 49(3), 359-363.
[http://dx.doi.org/10.1177/2168479015570337] [PMID:  30222394] 
[197] 
Wang, S.M.; Han, C.; Bahk, W.M.; Lee, S.J.; Patkar, A.A.; Masand, P.S.; Pae, C.U. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med. J.,  2018, 54(2), 101-112.
[http://dx.doi.org/10.4068/cmj.2018.54.2.101] [PMID:  29854675] 
[198] 
Goodman, W.K.; Murphy, T.K.; Storch, E.A. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl.),  2007, 191(1), 87-96.
[http://dx.doi.org/10.1007/s00213-006-0642-6] [PMID:  17180618] 
[199] 
Hogg, S.; Ansari, S.; Masood, Q.; Agius, M.; Rihmer, Z. Are SSRIs responsible for precipitating suicidal ideation in teenagers with ‘subsyndromal’ bipolar affective disorder who have been misdiagnosed with unipolar depression? Psychiatr. Danub.,  2016, 28(Suppl. 1), 79-82.
[PMID:  27663811] 
[200] 
Bala, A.; Nguyen, H.M.T.; Hellstrom, W.J.G. Post-SSRI sexual dysfunction: a literature review. Sex. Med. Rev.,  2018, 6(1), 29-34.
[http://dx.doi.org/10.1016/j.sxmr.2017.07.002] [PMID:  28778697] 
[201] 
Popova, N.K.; Amstislavskaya, T.G. Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice. Psychoneuroendocrinology,  2002, 27(5), 609-618.
[http://dx.doi.org/10.1016/S0306-4530(01)00097-X] [PMID:  11965359] 
[202] 
Godwin, M.; Seguin, R. Critical appraisal skills of family physicians in Ontario, Canada. BMC Med. Educ.,  2003, 3, 10.
[http://dx.doi.org/10.1186/1472-6920-3-10] [PMID:  14651755] 
[203] 
Mojtabai, R.; Olfson, M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff. (Millwood),  2011, 30(8), 1434-1442.
[http://dx.doi.org/10.1377/hlthaff.2010.1024] [PMID:  21821561] 
Cite As
Current Neuropharmacology

Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)

Abstract

Graphical Abstract
